# Regadenoson Real Time Perfusion Imaging Trial-Optison

> **NCT01489176** · PHASE3 · COMPLETED · sponsor: **University of Nebraska** · enrollment: 50 (actual)

## Conditions studied

- Coronary Artery Disease
- Myocardial Perfusion Abnormalities

## Interventions

- **DRUG:** Regadenoson; Optison

## Key facts

- **NCT ID:** NCT01489176
- **Lead sponsor:** University of Nebraska
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07-31
- **Primary completion:** 2014-04-01
- **Final completion:** 2014-12-01
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2024-10-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01489176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01489176, "Regadenoson Real Time Perfusion Imaging Trial-Optison". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01489176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*